Vinci Pharmaceuticals Inc. schließt Serie-A-Finanzierung über mehr als 8 Millionen US-Dollar zur Weiterentwicklung der EPIPLANT™-Wirkstofffreisetzungsplattform ab

EPIPLANT™Positive

AI Analysis

Summary

Vinci Pharmaceuticals completed a Series A financing round of over $8 million to advance its EPIPLANT drug release platform, bringing total capital raised to over $16.5 million including previous seed funding.

Importance:5/10

Sentiment:

0.60

Series A FundingDrug Delivery PlatformCapital Raising

Read the original article

Published by PR Newswire Pharma on October 8, 2026 6:41 PM

Read Original